Correction to: Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer

BMC Cancer. 2019 Jun 24;19(1):620. doi: 10.1186/s12885-019-5831-x.

¹ Mayo Clinic, 4500 San Pablo Rd. S, Jacksonville, FL, 32224, USA. Perez.edith@mayo.edu.
² F. Hoffmann-La Roche Ltd, Grenzacherstrasse 124, 4070, Basel, Switzerland.
³ Interdisciplinary Oncology Center, Nussbaumstrasse 12, 80336, Munich, Germany.
⁴ PUCRS School of Medicine, Av. Ipiranga 6681, Porto Alegre, RS, 90619-900, Brazil.
⁵ Graduate School of Medicine, Kyoto University, Yoshida-Konoe-cho, Sakyo-ku, Kyoto, 606-8501, Japan.
⁶ Samsung Medical Centre, 81 Irwon-Ro Gangnam-gu, Seoul, 06351, South Korea.
⁷ Department of Surgery, Oncology and Gastroenterology, University of Padova and Istituto Oncologico Veneto, Via Gattamelata 64, 35128, Padova, Italy.
⁸ Instituto de Investigacion Sanitaria Gregorio Marañón, CIBERONC, GEICAM, Universidad Complutense, Avda. de Séneca, 2, 28040, Madrid, Spain.
⁹ Postgraduate Medical Education Center, ul. Marymoncka 99, 02-813, Warsaw, Poland.
¹⁰ Paul Strauss Cancer Center, 3 Rue de la Porte de l'Hôpital, BP 30042, 67065, Strasbourg, France.
¹¹ Sarah Cannon Research Institute and Tennessee Oncology, PLLC, 250 25th Ave N, Nashville, TN, 37203, USA.
¹² Guys Hospital and Sarah Cannon Research Institute, Great Maze Pond, London, SE1 9RT, UK.

Abstract

Following publication of the original article [1], the authors reported the following errors in the article.